tag:blogger.com,1999:blog-7857054149675424609.post9125101434499626886..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Biotech IPOs Show Wall Street Likes New ToysDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-87050943109926563252013-06-20T12:19:30.900+00:002013-06-20T12:19:30.900+00:00In time the best science will be recognized as wil...In time the best science will be recognized as will impressive clinical results. Valuations will ultimately reflect the intrinsic value of the company. It may take a while, but companies like Arrowhead and Benitec will eventually shine bright.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-79606866632485284112013-06-19T18:24:39.491+00:002013-06-19T18:24:39.491+00:00It is not surprising that companies such as Arrowh...It is not surprising that companies such as Arrowhead are inefficiently priced. Strikes against it include limited institutional ownership, a low stock price and market cap that often bar such institutional ownership, low average trading volume, a shaky financial history, and an unproven clinical track record.<br /> <br />Yet even though it is not reflected in the stock price, ARWR is a tettrazininoreply@blogger.com